FDA Inspection 1044877 — Cadila Pharmaceuticals Limited

Cadila Pharmaceuticals Limited — FEI 3002806711

The FDA completed an inspection of Cadila Pharmaceuticals Limited on February 13, 2018 in Ankleshwar. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
February 13, 2018
Fiscal Year
2018
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Ankleshwar (India)